Project Grant R01CA317908
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $724K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded $435,243 to Weill Medical College of Cornell University on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate GSK3 relocalizing peptides as anti-cancer therapeutics. The recipient will assess the anti-cancer efficacy of GSK3 RNLS-peptide both as a standalone therapy and in combination with the chemotherapeutic agent 5-fluorouracil. The work employs multiple orthotopic mouse models of lung, brain, and colorectal...
- The National Cancer Institute awarded Weill Medical College of Cornell University $716,183 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate and target co-inhibitory and co-stimulatory molecules in CAR T-cell therapies. The award funds research to overcome clinical barriers in adoptive cell therapies with chimeric antigen receptors, which show promise for cancer treatment but face challenges including insufficient T-cell persistence, antigen escape, and...
- The National Cancer Institute awarded Weill Medical College of Cornell University $733,149 on September 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate immune-related adverse events (IRAE) driven by anti-PD1 immunotherapy in cancer patients. The research integrates patient-centered clinical investigation with advanced omics pipelines using human specimens, leveraging a multidisciplinary approach spanning human and mouse tissue and tumor immunology. The...
- The National Cancer Institute awarded Weill Medical College of Cornell University $703,423 on a Project Grant (R01CA306020) effective June 1, 2026 under the Cancer Biology Research program (CFDA 93.396). The award funds research to identify molecular targets for mitigating immune-related adverse events (IRAEs) triggered by immunotherapy, particularly immune checkpoint blockade agents used in cancer treatment. IRAEs occur in 20–30 percent of cancer patients receiving these agents, with skin and...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...
- The National Cancer Institute awarded Weill Medical College of Cornell University $435,827 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop autologous lymph node T cells engineered to overcome treatment-resistant lung cancer. The research addresses the limited effectiveness of adoptive T-cell therapy in solid tumors by utilizing polyclonal cohorts of multipotent T cells derived from tumor-draining lymph nodes rather than peripheral blood. Prior work...
- The National Cancer Institute awarded the Research Foundation of the City University of New York $431,222 on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop radiotherapeutic paradigms for desmoplastic small round cell tumor (DSRCT), an extremely rare abdominal and pelvic soft tissue sarcoma with a five-year survival rate under 15% and no current standard-of-care treatment. The recipient will synthesize, characterize, and validate 177Lu-, 225Ac-, and...
- The National Cancer Institute awarded Icahn School of Medicine at Mount Sinai $697,131 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate myeloid-stromal interactions that drive immune suppression in colorectal cancer and to evaluate therapeutic strategies targeting these pathways. The research addresses the immunological resistance of microsatellite-stable colorectal cancer to immune checkpoint blockade, particularly in patients with liver metastases. The...
- The National Cancer Institute awarded Health Research, Inc. (Roswell Park Division), doing business as Health Research At Roswell Park, $446,112 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct enhanced targeted therapy research for colorectal cancer. The research tests the synergistic potential of combining MAPK kinase cascade inhibitors with ribavirin, a GTP synthesis inhibitor, against BRAF- and RAS-mutated colorectal cancer. Work includes testing...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...